US Patent

US8026276 — Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant

Formulation · Assigned to Wyeth LLC · Expires 2026-01-20 · 0y expired

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects parenteral formulations of the drug CCI-779, including specific formulations with cosolvents, antioxidants, and surfactants.

USPTO Abstract

Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US8026276
Jurisdiction
US
Classification
Formulation
Expires
2026-01-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.